[go: up one dir, main page]

WO2001047512A3 - Method for relieving pain associated with an internal disease site - Google Patents

Method for relieving pain associated with an internal disease site Download PDF

Info

Publication number
WO2001047512A3
WO2001047512A3 PCT/US2000/042661 US0042661W WO0147512A3 WO 2001047512 A3 WO2001047512 A3 WO 2001047512A3 US 0042661 W US0042661 W US 0042661W WO 0147512 A3 WO0147512 A3 WO 0147512A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
disease site
interior
relieving agent
relieving
Prior art date
Application number
PCT/US2000/042661
Other languages
French (fr)
Other versions
WO2001047512A2 (en
Inventor
George A Luiken
Original Assignee
Fluoro Probe Inc
George A Luiken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fluoro Probe Inc, George A Luiken filed Critical Fluoro Probe Inc
Priority to AU49041/01A priority Critical patent/AU4904101A/en
Publication of WO2001047512A2 publication Critical patent/WO2001047512A2/en
Publication of WO2001047512A3 publication Critical patent/WO2001047512A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods are provided for in vivo administration of a pain-relieving drug, such as a local anesthetic (e.g. lidocaine), to an interior disease site for pain relief at the interior disease site. In the invention pain treatment methods, a subject is administered a targeting construct comprising a biologically compatible pain-relieving agent and a tumor-avid ligand or monoclonal antibody that preponderantly binds to or is taken up by the tissue associated with an interior disease site. Administration is by a method other than topical injection or application, such as parenteral injection. Because the pain-relieving agent is delivered by the ligand to the disease site, intractable pain situated in the interior of the body, such as is caused by various tumors, can be managed using a lower level of the pain-relieving agent then is required when the pain-relieving agent is injected in the free state.
PCT/US2000/042661 1999-12-08 2000-12-06 Method for relieving pain associated with an internal disease site WO2001047512A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU49041/01A AU4904101A (en) 1999-12-08 2000-12-06 Method for relieving pain associated with an internal disease site

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45749899A 1999-12-08 1999-12-08
US09/457,498 1999-12-08

Publications (2)

Publication Number Publication Date
WO2001047512A2 WO2001047512A2 (en) 2001-07-05
WO2001047512A3 true WO2001047512A3 (en) 2002-05-02

Family

ID=23816983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042661 WO2001047512A2 (en) 1999-12-08 2000-12-06 Method for relieving pain associated with an internal disease site

Country Status (2)

Country Link
AU (1) AU4904101A (en)
WO (1) WO2001047512A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1481673A4 (en) * 2002-02-05 2008-09-24 Ajinomoto Kk Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
FR2902341B1 (en) 2006-06-16 2011-02-25 Scras THERAPEUTIC USE SIMULTANEOUS, SEPARATE OR SPREAD IN THE TIME OF AT LEAST ONE BOTULINUM NEUROTOXIN, AND AT LEAST ONE OPIACEOUS DERIVATIVE
FR2910327B1 (en) 2006-12-22 2013-04-26 Scras USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR TREATING PAIN INDUCED BY THERAPEUTIC TREATMENTS OF AIDS VIRUS.
FR2930447B1 (en) 2008-04-25 2010-07-30 Sod Conseils Rech Applic THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN FOR THE TREATMENT OF PAIN IN THE CASE OF DIABETIC NEUROPATHY
RU2648449C2 (en) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
US20150098997A1 (en) 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Treating Attention Deficit Hyperactivity Disorder, Anxiety and Insomnia Using Dexmedetomidine Transdermal Compositions
CN110585173A (en) 2013-10-07 2019-12-20 帝国制药美国公司 Dexmedetomidine transdermal delivery device and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
WO1999017806A1 (en) * 1997-10-08 1999-04-15 The Speywood Laboratory Limited Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
WO2000021576A2 (en) * 1998-10-15 2000-04-20 Fluoro Probe, Inc. Method for viewing tumor tissue located within a body cavity
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983586A (en) * 1987-12-30 1991-01-08 University Of Florida Pharmaceutical formulations for parenteral use
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
WO1999017806A1 (en) * 1997-10-08 1999-04-15 The Speywood Laboratory Limited Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics
WO2000021576A2 (en) * 1998-10-15 2000-04-20 Fluoro Probe, Inc. Method for viewing tumor tissue located within a body cavity
WO2001053336A1 (en) * 2000-01-19 2001-07-26 Allergan Sales, Inc. Clostridial toxin derivatives and methods for treating pain

Also Published As

Publication number Publication date
WO2001047512A2 (en) 2001-07-05
AU4904101A (en) 2001-07-09

Similar Documents

Publication Publication Date Title
Onofrio et al. Long-term pain relief produced by intrathecal morphine infusion in 53 patients
Tsui et al. Dextrose 5% in water: fluid medium for maintaining electrical stimulation of peripheral nerves during stimulating catheter placement
US8512292B2 (en) Infiltration cannula
CA2369810A1 (en) Method of treating pain
WO2004011055A3 (en) Implantable or insertable medical devices for controlled drug delivery
WO2010040559A3 (en) Infusion of drugs
WO2003028765A1 (en) Injections for eye tissue containing drug bound to polyethylene glycol
ATE235257T1 (en) COMPOSITION FOR TREATING MALIGNANT TUMORS AND THEIR METASTASIS
LUTZ et al. Management of postoperative pain: review of current techniques and methods
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
Dinsmore et al. Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel
WO2001047512A3 (en) Method for relieving pain associated with an internal disease site
WO2004032858A3 (en) Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics
Gilmer-Hill et al. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer
Shulman et al. Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer
US10420923B1 (en) Method and device for intrathecal administering of immunoglobulin
Perren et al. Spinal cord lesion after long-term intrathecal clonidine and bupivacaine treatment for the management of intractable pain
Krames The chronic intraspinal use of opioid and local anesthetic mixtures for the relief of intractable pain: when all else fails!
Kvolik et al. A wound infiltration as a method of postoperative analgesia
KONTANI et al. A study of morphine-induced urinary retention in anesthetized rats capable of micturition
Kumar et al. Hydromorphone in the management of cancer-related pain: an update on routes of administration and dosage forms
Kasdan et al. Extravasation of phenytoin and diazepam requiring surgical debridement and skin grafting
SE9901257D0 (en) Treatment of pain after joint surgery
Stief et al. Intracavernous drug delivery system: an alternative to intracavernous injection in the treatment of impotence?
Yan et al. Selective Regional Anesthesia Options in Surgical Subspecialties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP